Top

Published in:

01-07-2021 | Barrett Esophagus | 2020 SAGES Oral

Somatic DNA copy number alterations in non-dysplastic Barrett’s esophagus

Authors: Zachary M. Callahan, Wennuan Liu, Jun Hou, S. Lilly Zheng, Jamaal Rehman, H. Mason Hedberg, Craig S. Brown, Bailey Su, Mikhail Attaar, Kristine Kuchta, MaryAnn Regner, JoAnn Carbray, Jianfeng Xu, Michael Ujiki

Published in: Surgical Endoscopy | Issue 7/2021

Abstract

Background

The purpose of this study was to analyze non-dysplastic Barrett’s esophagus (NDBE) biopsy tissue and compare the rate of somatic DNA copy number alterations (CNAs) in patients who subsequently progressed to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) to those patients who did not.

Methods

A retrospectively collected database of Barrett’s esophagus (BE) patients spanning a 16-year period was queried. Patients who progressed from NDBE to HGD or EAC were identified and compared to patients who did not. Initial biopsy specimens were microdissected and extracted DNA underwent Multiplex Ligation-dependent Probe Amplification (MLPA) for CNAs. Comparisons between progressors and non-progressors were made with Fisher’s exact and two-sample t tests. Logistic regression assessed factors associated with progression.

Results

Of the 2459 patients in the BE database, 36 patients progressed from NDBE to either HGD or EAC. There were eight progressors who had biopsy specimens with adequate DNA for analysis. The progressor and non-progressor cohort had similar demographic information and medical history. The progressor group trended towards being older at diagnosis (72 ± 10 vs. 64 ± 13 years, p = 0.097) and fewer progressors reported reflux symptoms (50 vs. 94.7%, p < 0.001). Progressor specimens had more overall CNAs (75% vs. 33.6%, p = 0.026). On univariable analysis, there was an association between progression and absence of GERD symptoms (OR 16.54 [3.42–80.03], p = 0.001), any CNA (OR 5.10 [1.18–23.30], p = 0.035), and CNA in GATA6 or ERBB2 (OR 6.72 [1.18–38.22], p = 0.032).

Conclusions

Patients who progressed from NDBE to HGD or EAC were older at first diagnosis of BE and fewer of the progressors reported symptoms of reflux when compared to non-progressors. Progression was associated with the presence of any CNA and specific CNAs in GATA6 or ERBB2.

Runge TM, Abrams JA, Shaheen NJ (2015) Epidemiology of barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol Clin N Am 44:203–231. https://doi.org/10.1016/j.gtc.2015.02.001CrossRef

Anaparthy R, Gaddam S, Kanakadandi V, Alsop BR, Gupta N, Higbee AD, Wani SB, Singh M, Rastogi A, Bansal A, Cash BD, Young PE, Lieberman DA, Falk GW, Vargo JJ, Thota P, Sampliner RE, Sharma P (2013) Association between length of Barrett’s esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol 11:1430–1436. https://doi.org/10.1016/j.cgh.2013.05.007CrossRefPubMed

Wani S, Falk G, Hall M, Gaddam S, Wang A, Gupta N, Singh M, Singh V, Chuang K-Y, Boolchand V, Gavini H, Kuczynski J, Sud P, Reddymasu S, Bansal A, Rastogi A, Mathur SC, Young P, Cash B, Lieberman DA, Sampliner RE, Sharma P (2011) Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 9:220–227. https://doi.org/10.1016/j.cgh.2010.11.008 (quiz e26)CrossRefPubMed

Duits LC, van der Wel MJ, Cotton CC, Phoa KN, Ten Kate FJW, Seldenrijk CA, Offerhaus GJA, Visser M, Meijer SL, Mallant-Hent RC, Krishnadath KK, Pouw RE, Tijssen JGP, Shaheen NJ, Bergman JJGHM (2017) Patients with Barrett’s esophagus and confirmed persistent low-grade dysplasia are at increased risk for progression to neoplasia. Gastroenterology 152:993–1001.e1. https://doi.org/10.1053/j.gastro.2016.12.008CrossRefPubMed

Callahan ZM, Shi Z, Su B, Xu J, Ujiki M (2019) Genetic variants in Barrett’s esophagus and esophageal adenocarcinoma: a literature review. Dis Esophagus. https://doi.org/10.1093/dote/doz017CrossRefPubMed

Gordon LG, Mayne GC, Hirst NG, Bright T, Whiteman DC, Australian Cancer Study Clinical Follow-Up Study, Watson DI (2014) Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc 79:242–56.e6. https://doi.org/10.1016/j.gie.2013.07.046CrossRefPubMed

Bird-Lieberman EL, Dunn JM, Coleman HG, Lao-Sirieix P, Oukrif D, Moore CE, Varghese S, Johnston BT, Arthur K, McManus DT, Novelli MR, O’Donovan M, Cardwell CR, Lovat LB, Murray LJ, Fitzgerald RC (2012) Population-based study reveals new risk-stratification biomarker panel for Barrett’s esophagus. Gastroenterology 143:927–35.e3. https://doi.org/10.1053/j.gastro.2012.06.041CrossRefPubMed

Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, Shim B, Ramos AH, Saksena G, Baca SC, Baselga J, Tabernero J, Barretina J, Enzinger PC, Corso G, Roviello F, Lin L, Bandla S, Luketich JD, Pennathur A, Meyerson M, Ogino S, Shivdasani RA, Beer DG, Godfrey TE, Beroukhim R, Bass AJ (2012) Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 72:4383–4393. https://doi.org/10.1158/0008-5472.CAN-11-3893CrossRefPubMedPubMedCentral

Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho Y-J, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao M-S, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463:899–905. https://doi.org/10.1038/nature08822CrossRefPubMedPubMedCentral

10.

Weaver JMJ, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, Murtaza M, Ong C-AJ, Lao-Sirieix P, Dunning MJ, Smith L, Smith ML, Anderson CL, Carvalho B, O’Donovan M, Underwood TJ, May AP, Grehan N, Hardwick R, Davies J, Oloumi A, Aparicio S, Caldas C, Eldridge MD, Edwards PAW, Rosenfeld N, Tavaré S, Fitzgerald RC, OCCAMS consortium (2014) Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 46:837–843. https://doi.org/10.1038/ng.3013CrossRefPubMedPubMedCentral

11.

Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS (2001) Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96:2839–2848. https://doi.org/10.1111/j.1572-0241.2001.04236.xCrossRefPubMedPubMedCentral

12.

Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ (2007) NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4:e67. https://doi.org/10.1371/journal.pmed.0040067CrossRefPubMedPubMedCentral

13.

Li X, Galipeau PC, Paulson TG, Sanchez CA, Arnaudo J, Liu K, Sather CL, Kostadinov RL, Odze RD, Kuhner MK, Maley CC, Self SG, Vaughan TL, Blount PL, Reid BJ (2014) Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett’s esophagus. Cancer Prev Res 7:114–127. https://doi.org/10.1158/1940-6207.CAPR-13-0289CrossRef

14.

Findlay JM, Middleton MR, Tomlinson I (2016) Genetic biomarkers of Barrett’s esophagus susceptibility and progression to dysplasia and cancer: a systematic review and meta-analysis. Dig Dis Sci 61:25–38. https://doi.org/10.1007/s10620-015-3884-5CrossRefPubMed

15.

Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Blount PL, Reid BJ (2004) The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 64:7629–7633. https://doi.org/10.1158/0008-5472.CAN-04-1738CrossRefPubMed

16.

Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, Gray JW (1992) ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89:5321–5325. https://doi.org/10.1073/pnas.89.12.5321CrossRefPubMedPubMedCentral

17.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu M-C, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay M-A, Riva A, Crown J, Breast Cancer International Research Group (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283. https://doi.org/10.1056/NEJMoa0910383CrossRefPubMedPubMedCentral

Title: Somatic DNA copy number alterations in non-dysplastic Barrett’s esophagus
Authors: Zachary M. Callahan
Wennuan Liu
Jun Hou
S. Lilly Zheng
Jamaal Rehman
H. Mason Hedberg
Craig S. Brown
Bailey Su
Mikhail Attaar
Kristine Kuchta
MaryAnn Regner
JoAnn Carbray
Jianfeng Xu
Michael Ujiki
Publication date: 01-07-2021
Publisher: Springer US
Keyword: Barrett Esophagus
Published in: Surgical Endoscopy / Issue 7/2021
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-020-07859-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Somatic DNA copy number alterations in non-dysplastic Barrett’s esophagus

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2021

Initial management of esophageal anastomotic strictures after transhiatal esophagectomy for esophageal cancer with dilations up to 18–20 mm

Appropriate patient selection facilitates safe discharge from the PACU after laparoscopic ventral hernia repair: an analysis of the AHSQC database

The risk factors for incisional hernia after laparoscopic colorectal surgery: a multicenter retrospective study at Yokohama Clinical Oncology Group

Short-term outcome of routine use of EndoFLIP during hiatal hernia repair

Complications of feeding jejunostomy placement: a single-institution experience

A validated score predicting common bile duct stone in patients hospitalized with acute calculus cholecystitis: a multi-center retrospective study